Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

New ABCA12 gene mutations were linked to a skin condition with scaling and hair loss, and a treatment helped with hair loss in a related case.

This study suggests that monitoring CD8+ TEMRA cells in patients with rapidly progressive alopecia areata treated with intravenous corticosteroids could help predict therapeutic outcomes.

In this study, the researchers developed a hydrogel mimicking the fetal environment that significantly accelerated wound healing and hair follicle regeneration in vivo, with over 94% wound closure in 14 days, surpassing hydrogels lacking certain additives.

In this retrospective cohort study, researchers reported that 11.5% of patients with DRESS developed significant long-term autoimmune or renal sequelae, with age influencing the type of sequelae observed.

This study describes a new method for extracting red mordant dyes from wool fibers using ethylene diamine tetraacetic acid and N,N-dimethyl formamide, preserving the fibers for further examination.

This study suggests that long-term treatment with the contact sensitizer SADBE in mice may reduce leucocyte traffic in alopecia areata through impaired leucocyte extravasation.

In this study, 308-nm excimer light therapy showed significant effects in some patients with treatment-resistant alopecia universalis, suggesting it as a potential alternative therapy.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

This study found that the multifunctional exosome-based delivery platform EX104 reversed hair follicle miniaturization and promoted hair growth in a mouse model of androgenetic alopecia, performing comparably to minoxidil while also enhancing capillary growth and follicular proliferation.

This report describes a 28-year-old male with type 1 diabetes who presented with acrodermatitis enteropathica symptoms, highlighting potential challenges in blood glucose control linked to zinc deficiency.

This study found fractional carbon dioxide laser therapy effective in treating alopecia areata, both alone and with topical treatments, suggesting decorin's involvement in improving hair growth.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This case report identified two new SLC39A4 mutations in twin patients with acrodermatitis enteropathica, suggesting that different mutations in this gene may lead to varying clinical manifestations of the disorder.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

This study found that DEFB1 polymorphisms, specifically the rs1800972 CG and GG genotypes, may predict susceptibility to and severity of alopecia areata.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

This study reports that TFM-4AS-1, a selective androgen receptor modulator, promoted bone and muscle growth with reduced effects on reproductive organs in ovariectomized rats.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

This study used light sheet fluorescence microscopy to successfully image and analyze calcium oscillations in the root hairs of Arabidopsis thaliana, finding that these oscillations correlate with the root hair growth rate and that auxin affects these properties.

This study found that Eucommia ulmoides bark extract shows potential antioxidant and hair follicle-support properties in vitro and in vivo, but further validation is needed to confirm these effects.

This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This research found that exosome-derived long non-coding RNA AC010789.1, modified by FTO and hnRNPA2B1, enhanced human hair follicle stem cell proliferation against androgenic alopecia through the activation of S100A8/Wnt/β-catenin signaling pathways.

This study suggests that the rs2075876 variant in the AIRE gene may significantly increase susceptibility to alopecia areata in the examined male population.

This study found that the 308-nm Excimer laser was effective and safe for treating patchy alopecia areata in children, with hair regrowth observed in 60% of treated scalp patches.